Join SMi for their 2nd Annual Orphan Drugs & Rare Diseases conference as they showcase world leading experts speaking inclusively on the orphan drug industry featuring cutting edge research via case studies taking place in previously untreatable patients. The conference will highlight current regulatory policies involving the FDA & EMA, new drug discoveries and partnerships in clinical trials and drug development with patient groups. There will also be a 'big pharma spotlight session' highlighting where current pipelines stand and where the next blockbuster will be treating rare diseases, including discussions on HTA and pricing issues currently being implemented after recent reforms in Europe.KEY REASONS TO ATTENDReview through a unique 'Big Pharma Spotlight' session what drugs are finishing late stage clinical trials and where pipelines currently leadDiscover how market access and HTA are affecting Orphan Drug releasesReview optimal targeting for your new drug with expert analysis in patient selection and recruitmentLearn from case studies of new molecules in clinical trialsAnalyse current funding options; including financial and economic reimbursement for the clinical development of drugs KEYNOTE SPEAKERS:Kevin Lee, CSO, Rare Disease Research Unit, PfizerTony Hall, Founder, FindacureAdrien Lamoine, Director, GlaxoSmithKlineBarbara Polek, Supply Chain Manager, Santhera PharmaceuticalsFernando Royo, VP, International Government Affairs, GenzymeCamille Métais, Sr Regulatory Affairs Manager, Alexion PharmaDavid King, Director, Regulatory Policy and Intelligence, Novo NordiskKarl Petrovsky, Senior Manager-Industry Affairs, BaxterEstelle de Barbeyrac, Regulatory Affairs, Genethon